GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Bcl2l1 | multiple interactions | ISO | BCL2L1 (Homo sapiens) | 6480464 | CTD | [arsenic trioxide co-treated with epigallocatechin gallate] results in decreased expression of BCL2L1 protein; [Ibuprofen co-treated with epigallocatechin gallate] results in decreased expression of BCL2L1 mRNA alternative form; [Ibuprofen co-treated with epigallocatechin gallate] results in increased expression of BCL2L1 mRNA alternative form; calyculin A inhibits the reaction [[Ibuprofen co-treated with epigallocatechin gallate] results in decreased expression of BCL2L1 mRNA alternative form]; calyculin A inhibits the reaction [[Ibuprofen co-treated with epigallocatechin gallate] results in increased expression of BCL2L1 mRNA alternative form]; tautomycin inhibits the reaction [[Ibuprofen co-treated with epigallocatechin gallate] results in decreased expression of BCL2L1 mRNA alternative form]; tautomycin inhibits the reaction [[Ibuprofen co-treated with epigallocatechin gallate] results in increased expression of BCL2L1 mRNA alternative form] | PMID:18348186 PMID:20950636 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |